Clinical Trial

Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 10, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Based on a central role of inflammation in pancreas cancer, the role of IL 1 in acute and chronic inflammation , the inhibitory effect of IL 1 alfa and beta by anakinra and preliminary experience with anakinra in combination with chemotherapy in metastasis (with FOLFIRINOX) and localized disease (with gemcitabine/abraxane/cisplatin), a phase 2 study with anakinra in combination with perioperative chemotherapy for patients with PDAC is being proposed.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-06-08.
Status change: Not Yet Recruiting → Recruiting 2025-11-05
Trial Details
NCT Number NCT04926467
Lead Sponsor Baylor Research Institute
Conditions Pancreatic Adenocarcinoma
Enrollment 24 participants
Start Date 2021-07-23
Primary Completion 2026-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-11-10